abstract |
Disclosed is a polypeptide encoding a mutated oligoadenylate synthetase 1 (OAS 1). This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also disclosed is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS 1, including antisense oligonucleotides, methods, and compositions specific for human OASI, are also provided. |